Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875648 | 0.84 | BTN3A1 (0.56) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL14044811 | 0.82 | BTN3A1 (0.53) | L3MBTL1MEN1KMT2AHTT | |
| SCHEMBL28445426 | 0.81 | SRC (0.46) | L3MBTL1MAPK1MEN1KMT2AHTT | |
| SCHEMBL13622273 | 0.80 | BTN3A1 (0.44) | L3MBTL1MEN1KMT2A | |
| SCHEMBL19650266 | 0.78 | BTN3A1 (0.57) | ELANEMAPTMEN1KMT2AHTT | |
| SCHEMBL10579152 | 0.76 | ALDH1A1 (0.52) | ALDH1A1ELANESMN1; SMN2MAPTGAA | |
| SCHEMBL18961988 | 0.76 | ELANE (0.54) | ALDH1A1ELANETP53KLK1PRTN3 | |
| SCHEMBL12621310 | 0.76 | ELANE (0.54) | ALDH1A1ELANETP53KLK1PRTN3 | |
| SCHEMBL12621327 | 0.76 | ELANE (0.48) | ALDH1A1ELANETP53SMN1; SMN2KLK1 | |
| SCHEMBL17340249 | 0.76 | ELANE (0.48) | ALDH1A1ELANETP53SMN1; SMN2KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| WO-2020201751-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2020-10-08 | — | — | WO | disclosed |
| EP-3683225-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | Nucana PLC (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | NuCana plc (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-3224268-B1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2019-06-26 | — | — | EP | disclosed |
| EP-3224268-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana BioMed Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| WO-2017098252-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES AND OF THE GEMCITABINE PRODRUG NUC-1031 | NUCANA BIOMED LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| WO-2016083830-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | ALDH1A1 2246/4885L3MBTL1 725/4885MAPK1 2414/4885 |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | TYMP, DTYMK, TYMS | ALDH1A1 3512/4885L3MBTL1 2350/4885MAPK1 2197/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | ALDH1A1 2198/4885L3MBTL1 741/4885MAPK1 2511/4885 |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | ALDH1A1 2162/4885L3MBTL1 725/4885MAPK1 2565/4885 |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | MTAP, RNMT, ADA | ALDH1A1 2162/4885L3MBTL1 725/4885MAPK1 2565/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | ALDH1A1 2246/4885L3MBTL1 725/4885MAPK1 2414/4885 |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | ALDH1A1 2194/4885L3MBTL1 712/4885MAPK1 2406/4885 |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | ALDH1A1 2194/4885L3MBTL1 712/4885MAPK1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.